-+ 0.00%
-+ 0.00%
-+ 0.00%

Century Therapeutics Presents CNTY-813 Nonclinical Data At EASD 2026

Benzinga·10/02/2026 12:09:04

Data demonstrated scalable production, in vivo function and immune evasion, and updated progress toward clinical dosing of CNTY-813, Century's iPSC-derived islet replacement therapy for type 1 diabetes

CNTY-813 IND submission remains on track for Q4 2026; initial clinical data anticipated in the second half of 2027